Family History of Cancer in Relation to Breast Cancer Subtypes in African American Women by Bethea, Traci N. et al.
Family history of cancer in relation to breast cancer subtypes in 
African American women
Traci N. Bethea1, Lynn Rosenberg1, Nelsy Castro-Webb1, Kathryn L. Lunetta2, Lara E. 
Sucheston-Campbell3, Edward A. Ruiz-Narváez1, Marjory Charlot4, Song-Yi Park5, Elisa V. 
Bandera6, Melissa A. Troester7, Christine B. Ambrosone3, and Julie R. Palmer1
1Slone Epidemiology Center at Boston University, Boston, MA
2Boston University School of Public Health, Boston, MA
3Roswell Park Cancer Institute, Buffalo, NY
4Boston University School of Medicine, Boston, MA
5University of Hawaii Cancer Center, Honolulu, HI
6Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
7University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, 
NC
Abstract
Background—Evidence on the relation of family history of cancers other than breast cancer to 
breast cancer risk is conflicting and most studies have not assessed specific breast cancer subtypes.
Methods—We assessed the relation of first degree family history of breast, prostate, lung, 
colorectal, ovarian, cervical cancer, and lymphoma or leukemia, to risk of estrogen receptor 
positive (ER+), ER−, and triple negative breast cancer in data from the African American Breast 
Cancer Epidemiology and Risk Consortium. Multivariable logistic regression models were used to 
calculate odds ratios (ORs) and 95% confidence intervals (CIs).
Results—There were 3,023 ER+ and 1,497 ER− breast cancer cases (including 696 triple 
negative cases) and 17,420 controls. First degree family history of breast cancer was associated 
with increased risk of each subtype: OR=1.76 (95% CI 1.57–1.97) for ER+, 1.67 (1.42–1.95) for 
ER−, and 1.72 (1.38–2.13) for triple negative breast cancer. Family history of cervical cancer was 
associated with increased risk of ER− (OR=2.39, 95% CI 1.36–4.20), but not ER+ cancer. Family 
history of both breast and prostate cancer was associated with increased risk of ER+ (3.40, 2.42–
4.79) and ER− (2.09, 1.21–3.63) cancer, but family history of both breast and lung cancer was 
associated only with ER− cancer (2.11, 1.29–3.46).
Conclusions—A family history of cancers other than breast may influence risk of breast cancer 
and associations may differ by subtype.
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Impact—Greater surveillance and counseling for additional screening may be warranted for 
women with a family history of cancer.
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Introduction
Having a mother, sister, or daughter with a breast cancer diagnosis is a well-known risk 
factor for breast cancer.(1) Among African American women, estimates of the relative risk 
for first degree family history of breast cancer range from 1.65 to1.78,(2, 3) similar to 
findings from studies of European American and Asian women.(1, 4, 5) Among studies that 
reported results separately for estrogen receptor (ER) positive and ER− breast cancer, most 
reported similar associations by subtype,(3, 6–11) while one reported a stronger association 
with ER+ cancer(12) and two reported a stronger relation for ER− breast cancer.(13, 14) 
Only the Black Women’s Health Study reported on family history separately for ER+ and 
ER− breast cancer in African American women, with similar increases by subtype, but 
findings were based on small numbers.(3)
A first degree family history of cancers other than breast cancer may also increase breast 
cancer risk. Family history of prostate,(15, 16) lung,(17) ovarian,(18) and colon or colorectal 
cancer(3, 16) have been associated with greater risk of breast cancer in some, but not all 
studies that examined specific other cancers. In studies that examined combinations of 
cancers, risk of breast cancer was elevated for family history of breast and prostate cancers,
(15) breast and ovarian cancers,(19, 20) and breast and colorectal cancers.(16, 21, 22) 
Among African American women, family histories of lung cancer,(23) colon cancer,(3) or 
both breast and prostate cancer(16) were associated with increased risk of breast cancer.
The objective of the present study was to investigate the relation of first degree family 
history of breast and other cancers to risk of ER+, ER−, and triple negative breast cancer in 
African American women.
Materials and methods
The African American Breast Cancer Epidemiology and Risk (AMBER) Consortium has 
been described in detail elsewhere.(24) The AMBER Consortium pools data on African 
American women from two cohort studies, the Black Women’s Health Study and the 
Multiethnic Cohort Study, and two case-control studies, the Carolina Breast Cancer Study 
and the Women’s Circle of Health Study. Informed consent was provided to each study by 
its participants. Each study and the consortium were approved by the relevant Institutional 
Review Boards.
The Black Women’s Health Study (BWHS) is a prospective cohort study that enrolled 
59,000 African American women across the United States in 1995.(25) Participants were 
21–69 years old at baseline when they completed an extensive health questionnaire and are 
followed with biennial questionnaires for data on incident diagnoses and other factors. 
Bethea et al. Page 2
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Incident breast cancers are identified through self-report on questionnaires or through 
linkage to state cancer registries. For the AMBER Consortium, a nested case-control study 
was created; cohort participants without breast cancer were frequency-matched to cases 
based on age (5-year categories), geographic region, and most recent completed 
questionnaire.
The Multiethnic Cohort Study (MEC) is a prospective cohort study that enrolled men and 
women in Los Angeles county and Hawaii from 1993 through 1996.(26) Participants were 
45–75 years at baseline when they completed an extensive questionnaire and have been 
followed with questionnaires in 1999, 2003, and 2010 to update information. Breast cancer 
diagnoses are identified through linkage with the Los Angeles County Cancer Surveillance 
Program and the California Cancer Registry. A nested case-control study of African 
American women was created to pool MEC data with the AMBER Consortium. Controls, 
selected from women who had not developed breast cancer, were frequency-matched to 
cases on age (5-year categories) and most recent completed questionnaire,
The Carolina Breast Cancer Study (CBCS) is a case-control study that enrolled women in 
North Carolina from 1993 through 2001.(27) Participants were 20–74 years old and were 
interviewed in-person. Cases were identified through the North Carolina Central Cancer 
Registry, while controls were identified through Division of Motor Vehicle lists or Health 
Care Financing Administration lists. Controls were frequency-matched to cases based on 
age (5-year categories).
The Women’s Circle of Health Study is a case-control study that enrolled women in New 
York from 2003 through 2008 and in New Jersey beginning in 2006.(28) Recruitment in 
New Jersey is ongoing. Participants were 20–75 years old and were interviewed in-person 
for data collection. Cases were identified through New York City hospitals and the New 
Jersey State Cancer Registry, while controls were identified through random digit dialing 
and community-based recruitment.(29) Controls were frequency-matched to cases based on 
age (5-year categories).
Each study confirmed incident breast cancer cases with data on ER, progesterone receptor 
(PR), and human epidermal growth factor 2 receptor (HER2) obtained from medical records 
and/or state cancer registries.(24) Cases were classified as ER+, ER−, and triple negative 
(TN; ER−/PR−/HER2−). Of the 5,736 potential cases, ER status was available for 4,520 
cases (79%) at the time of this analysis. PR status was available for 4,301 cases (75%); 
HER2 status was available for fewer cases (2,927, 51%), due to more recent inclusion of 
HER2 in routine testing. There were no statistically significant differences between women 
with and without known receptor status by age or family history of breast cancer. In total, 
there were 3,023 ER+ cases, 1,497 ER− cases (including 696 triple negative cases), and 
17,420 controls.
Participants were asked whether any parent, sibling, or child (first degree relative) had been 
diagnosed with breast cancer and whether the relative was diagnosed before age 50. 
Participants were also asked about first degree family history of ovarian, colorectal, prostate, 
lung, and cervical cancer, and lymphoma or leukemia.
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Each study obtained detailed data on most known and suspected risk factors for breast 
cancer. Variables were centrally harmonized and evaluated as risk factors for breast cancer 
overall and for ER+, ER−, and TN breast cancer.(24, 30–33)
Statistical analysis
Multinomial logistic regression models were used to calculate odds ratios (ORs) and 95% 
confidence intervals (CIs) for the relation of family history of cancer to risk of ER+, ER−, 
and TN breast cancer. Multivariable models adjusted for the design variables – age (5-year 
categories), study (BWHS, CBCS, MEC, WCHS), geographic region (Northeast excluding 
New Jersey, New Jersey, South, Midwest, West), and questionnaire time period (1993–
1998, 1999–2005, 2006–2014) – and recency of mammogram (never had a mammogram, 
mammogram within past 2 years, last mammogram more than 2 years ago). Additional 
variables were also assessed as potential covariates, but were not associated with family 
history of cancer and did not appreciably change the effect estimates: years of education 
(<12, 12, 13–15, 16, >16 years), menopausal status and age at menopause 
(premenopausal,<45, 45–49, 50–54, ≥55 years), years of use of postmenopausal estrogen 
together with progesterone (never used, <5, ≥5 years), age at menarche (<11, 11–12, 13–14, 
15–16, ≥17 years), body mass index (<18.5, 18.5–24.9, 25–29.9, 30–34.9, 35–39.9, ≥40 
kg/m2), years of oral contraceptive use (never used/<1, 1–9, ≥10 years), parity (nulliparous, 
1, 2, 3, ≥4 births), age at first birth ( <25, ≥25 years), lactation (parous and never breastfed, 
parous and ever breastfed), pack-years of cigarette smoking (never smoked, <20, ≥20 pack-
years), and alcohol consumption (never drinker, former drinker, current drinker of <7 drinks/
week, current drinker of ≥7 drinks/week). The missing indicator method was used to handle 
missing values for covariates. To test for interaction between family history of cancer at 
different cancer sites, interactions were examined by introducing cross-product terms into 
the models.(34) Analyses were conducted using SAS 9.3 statistical package (SAS Institute 
Inc., Cary, NC). Random effects meta-analyses of study-specific results were conducted 
using Stata/SE 11.2 statistical software (StataCorp LP, College Station, TX), with results 
tested for heterogeneity by the Cochran’s Q statistic.(35)
Results
The prevalences of first degree family history of breast cancer and of cancers other than 
breast cancer were largely similar across studies (Table 1); the differences were statistically 
significant due to the large sample size. Among controls, 9.3% had a first degree relative 
with breast cancer and 22.7% had a first degree relative with a cancer other than breast 
cancer. Few controls had first-degree family history of both breast cancer and another cancer 
site (2.9%). Lung cancer was the most common other cancer among first degree relatives 
(7.7%), followed by prostate (7.6%) and colorectal cancer (6.2%).
The ORs for a first degree family history of breast cancer were similar by subtype: ER+ 
cancer (1.76, 95% CI 1.57–1.97), ER− cancer (1.67, 95% CI 1.42–1.95), and TN cancer 
(1.72, 95% CI 1.38–2.13) (Table 2). For each subtype, the ORs were higher if the relative 
was diagnosed before age 50. For example, for ER− cancer, the OR was 1.96 (95% 1.56–
2.46) for having a relative diagnosed with breast cancer before age 50 and 1.46 (95% 1.15–
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1.86) for a relative diagnosed at 50 or older. The ORs were also somewhat higher if the 
participant herself was diagnosed with breast cancer before age 45: the ORs for the 
association of having a first degree relative diagnosed with breast cancer before age 50 with 
risk of breast cancer before age 45 were all greater than 3.00 for ER+, ER− and TN breast 
cancer.
In assessing the relation of family history of other cancers to breast cancer risk, we looked 
first at risk of overall breast cancer. A first degree family history of breast cancer alone (with 
no other cancers among first degree relatives) was associated with a 1.58-fold risk (95% CI 
1.38–1.82) (Table 3). The ORs for family history of each of the other cancers alone were 
close to 1.0, with the exception of cervical cancer, for which the OR for the association with 
overall breast cancer risk was 1.53 (0.94–2.47). Risk of breast cancer was tripled in women 
who had a family history of both breast and prostate cancer (OR=3.02, 95% CI 2.19–4.16, p-
interaction<0.01). The OR for a family history of both breast and cervical cancer was 3.56 
(95% CI 0.99–12.85), but this estimate was based on only 7 exposed breast cancer cases. 
Risk of breast cancer was significantly increased for women with a family history of three or 
more cancer sites, but only when breast cancer was one of the sites.
Next, we considered family history of a cancer diagnosis in relation to risk of specific breast 
cancer subtypes. The ORs for first degree family history of breast cancer alone were similar 
for ER+, ER−, and TN breast cancer (Table 4). A family history of cervical cancer was 
associated with ER− (OR=2.56, 95% 1.44–4.53) and TN (OR=3.04, 95% CI 1.57–5.87) 
breast cancer, but not with ER+ cancer. A family history of lung cancer was associated with 
a 20% increase in risk of ER+ cancer (95% CI 1.04–1.48), while a family history of prostate 
cancer was associated with a 24% increase in risk of ER+ cancer (95% CI 1.00–1.44). There 
were no significant associations with family history of any of the other sites, although the 
OR for the association of family history of ovarian cancer with risk of TN breast cancer was 
elevated (OR=1.53, 95% CI 0.89–2.65). The OR for a family history of both breast and 
prostate cancer was 3.40 (95% CI 2.42–4.79) for ER+ cancer, as compared with 1.62 for 
breast alone (p-interaction=0.02), and was 2.09 (95% CI 1.21–3.63) for ER− cancer, as 
compared with 1.50 for breast alone (p-interaction=0.11); for TN breast cancer, the 
corresponding OR was 1.60, as compared with 1.54 for breast alone (p-interaction=0.62). 
The ORs for breast and lung and for breast and colorectal cancer were also higher, although 
not significantly higher, than for breast cancer alone for some subtypes. Having a family 
history of breast cancer and two or more other cancer sites was associated with increased 
risk of each subtype, with the ORs ranging from 2.42 for ER+ to 2.78 for ER− cancer.
Results were similar across the four studies. For example, the ORs for first-degree family 
history of breast cancer in relation to breast cancer risk were 1.74 (95% CI 1.51–2.02) in 
BWHS, 1.59 (95% CI 1.19–2.14) in CBCS, 1.88 (95% CI 1.50–2.35) in MEC, and 1.55 
(95% CI 1.22–1.97) in WCHS (p-heterogeneity=0.65). To assess the possibility of recall 
bias, we examined the associations separately in the case-control and cohort studies. The 
ORs for first-degree family history of breast cancer in relation to risk of breast cancer were 
1.57 (95% CI 1.31–1.90) in the case-control studies and 1.80 (95% CI 1.60–2.03) in the 
cohort studies (p-heterogeneity=0.23).
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Discussion
This large study provides convincing evidence that first degree family history of breast 
cancer is associated with ER+, ER−, and TN breast cancer in African American women and 
that having a relative diagnosed with breast cancer at a young age is a strong predictor of 
risk. Having a history of breast cancer together with prostate cancer was associated with a 
further increase in risk of each subtype. Family history of ovarian cancer was not associated 
with increased risk of ER+ or ER− cancer, but there was some evidence of a positive 
association with TN breast cancer. In addition, we observed an unexpected association of 
family history of cervical cancer with increased risk of ER− breast cancer.
Previous studies with data on African American women have also shown family history of 
breast cancer to be a strong risk factor for breast cancer.(2, 3, 16, 36–39) Only the BWHS 
and the Women’s CARE study also considered the relative’s age at diagnosis, and both 
observed a greater risk of breast cancer when the relative was diagnosed at a younger age.(2, 
3) In the only study to present data in African American women by subtype, the BWHS, a 
similar increase was observed across subtypes.(3)
Findings according to subtype from other populations have been mixed. The association 
with family history of breast cancer has been similar across breast cancer subtypes,(3, 6–11, 
40) stronger for ER+ breast cancer,(12, 41) and stronger for ER− or TN breast cancer.(13, 
14, 42) The strongest evidence comes from a pooled analysis of 12 studies in the Breast 
Cancer Association Consortium, where an association with family history of breast cancer 
was present across subtypes, but with a stronger association for basal-like breast cancer.(40)
Only a few studies of African Americans have examined the relation of family history of 
cancers other than breast cancer to risk of breast cancer.(3, 16) In the BWHS, a family 
history of colon cancer was associated with increased risk of breast cancer, with a relative 
risk estimate of 1.35, but the study did not consider whether participants also had a family 
history of breast cancer.(3) In the Women’s Health Initiative, having a family history of both 
breast and prostate cancers was associated with a 2.34-fold increase in risk of breast cancer.
(16) Neither of these studies presented data by breast cancer subtype. Limited data by 
subtype are available from other populations. In a predominantly European American 
population from the Iowa Women’s Health Study, a family history of prostate cancer was 
associated with increased risk of both ER+/PR+ and ER−/PR− breast cancer.(43) A family 
history of lung cancer was associated with increased risk of hormone receptor positive breast 
cancer in a case-control study in China.(44) No previous study has reported an association of 
family history of cervical cancer with increased risk of breast cancer.
Associations with family history of cancer could be explained in part by environmental or 
genetic factors shared within families. A family may have similar reproductive habits,(45–
47) dietary patterns,(48) physical activity,(49, 50) or body size,(51, 52) each of which 
influences risk of various cancers.(53) Although knowledge of a family history of cancer 
influences cancer screening, individuals with a family history of cancer do not differ in 
lifestyle from individuals without knowledge of a family history.(54–56) Genetics play a 
role in breast cancer etiology.(57, 58) Heritable mutations in BRCA1 or BRCA2 genes are 
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associated with increased risk of both breast cancer and ovarian cancer.(59, 60) Germline 
mutations in the BRCA1 and BRCA2 genes have also been associated with increased risk of 
prostate and colorectal cancers,(59–61) while germline mutations in the CHEK2 gene 
increase risk of breast, prostate, and colon cancers.(62)
Our observation of a strong increase in risk among participants with a family history of both 
breast and prostate cancer may relate to recent genetic findings. A family history of prostate 
cancer has been associated with mutation in the RNASEL gene in African Americans.(63) 
Mutations in this gene have also been associated with risk of breast and cervical cancers.(64) 
A potential mechanism linking the RNASEL gene and ER− breast cancer is inflammation. 
Inflammatory markers have been elevated in studies of hormone negative cancers.(65–67) 
RNASEL variants have been associated with elevated inflammatory biomarkers(68) and the 
enzyme encoded by the RNASEL gene has proinflammatory functions.(69)
Analyses of data from The Cancer Genome Atlas and other genomic data suggest that there 
are etiologic links between ovarian cancer and basal-like breast cancer,(70–73) which is 
primarily comprised of TN tumors. Consistent with those data, we observed a non-
significant 53% increase in risk of TN breast cancer associated with a first degree family 
history of ovarian cancer. Genomic analyses also suggest that there are biologic similarities 
between basal-like breast cancer and lung cancer.(72, 73) In our data, the risk of TN breast 
cancer was significantly increased for a first degree family history of lung cancer only in the 
presence of a first degree family history of breast cancer.
African American women experience a higher prevalence of early onset breast cancer and of 
ER− breast cancer compared to European American women.(74–76) Because of the large 
sample size, we were able to informatively assess breast cancer risk by age and for breast 
cancer subtypes. We were also able to assess family history of cancers other than breast 
cancer. We controlled for multiple potential confounding factors. Participants’ self-report of 
family history may have been incomplete and could have been subject to recall bias in the 
case-control studies. However, previous validation studies have shown that self-reported 
family cancer histories for first degree relatives are accurate for breast cancer(77) and results 
were similar across our studies, which included cohort studies in which family history data 
were provided before the participant was diagnosed with breast cancer. Additionally, the 
prevalence of family history of breast cancer among controls in the AMBER Consortium 
(9.3%) was similar to the prevalence in other studies.(78, 79) We did not have data on all 
cancer sites that may be of interest, such as the endometrium and pancreas.
In summary, the present findings suggest that family history of cancers other than breast 
cancer may indicate a higher inherited genetic susceptibility to breast cancer. Women who 
had both breast and prostate cancer-affected family members had a particularly high risk of 
both ER+ and ER− breast cancer. Greater surveillance and counseling for additional 
screening may be warranted.
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Table 3
Family history of breast cancer and cancer at six other sites in relation to risk of breast cancer.
First degree family history of Controls Cases ORa (95% CI)
No cancer 9,735 2,374 1.00 Reference
One cancer site
 Breast cancer 914 393 1.58 (1.38–1.82)
 Lung cancer 869 250 1.19 (1.01–1.39)
 Prostate cancer 863 244 1.16 (0.99–1.36)
 Colorectal cancer 624 171 1.17 (0.97–1.41)
 Ovarian cancer 323 61 0.90 (0.68–1.21)
 Lymphoma or leukemia 137 52 1.25 (0.88–1.78)
 Cervical cancer 52 34 1.53 (0.94–2.47)
Two cancer sites
 Breast/Prostate 105 76 3.02 (2.19–4.16)
 Breast/Lung 126 52 1.60 (1.13–2.27)
 Breast/Colorectal 83 32 1.40 (0.89–2.22)
 Breast/Ovarian 51 11 1.21 (0.62–2.37)
 Breast/Lymphoma or leukemia 16 10 1.42 (0.60–3.33)
 Breast/Cervical 5 7 3.56 (0.99–12.85)
 Prostate/Colorectal 119 37 1.52 (1.03–2.24)
 Prostate/Lung 73 25 1.54 (0.95–2.50)
 Prostate/Ovarian 28 12 1.95 (0.94–4.02)
 Prostate/Lymphoma or leukemia 17 9 2.39 (1.02–5.60)
 Lung/Colorectal 91 17 0.91 (0.53–1.55)
 Colorectal/Ovarian 27 10 1.73 (0.81–3.70)
 2 sites other than breast 88 24 0.94 (0.58–1.54)
Three or more cancer sites
 Breast/Prostate/Lung 17 11 3.05 (1.35–6.89)
 Breast/Lung/Colorectal 17 9 2.60 (1.12–6.03)
 Breast and 2 other sitesb 74 38 2.39 (1.57–3.64)
 ≥3 sites other than breast 47 15 1.37 (0.74–2.54)
a
Multivariable model adjusts for age, study, geographic region, questionnaire time period, and recency of mammogram
bOther than the listed combinations of cancer sites
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